[go: up one dir, main page]

AR051565A1 - DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4. - Google Patents

DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.

Info

Publication number
AR051565A1
AR051565A1 ARP050103666A ARP050103666A AR051565A1 AR 051565 A1 AR051565 A1 AR 051565A1 AR P050103666 A ARP050103666 A AR P050103666A AR P050103666 A ARP050103666 A AR P050103666A AR 051565 A1 AR051565 A1 AR 051565A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
het
alkynyl
cycloalkyl
Prior art date
Application number
ARP050103666A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR051565A1 publication Critical patent/AR051565A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Compuestos que demuestran efectos protectores en las células objetivo de la infeccion de VIH en una manera a fin de unirse específicamente al receptor de quimioquina, y los cuales afectan la union del ligante natural o quimioquina a un receptor tal como CXCR4 y/o CCR5 de una célula objetivo. Métodos de preparacion y composiciones farmacéuticas que los contienen y su uso para la fabricacion de medicamentos para el tratamiento de la infeccion por VIH y otras patologías. Reivindicacion 1: Un compuesto de la formula (1), en donde: t es 0, 1 o 2; cada R independientemente es H, alquil, alquenil, alquinil, haloalquil, cicloalquil, -RaAy, -RaOR10, o -RaS(O)qR10; cada R1 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; n es 0, 1 o 2; R2 se selecciona de un grupo que consiste de H, alquil, haloalquil, cicloalquil, alquenil, alquinil, -RaAy, -RaOR5, -RaS(O)qR5, o -Racicloalquil, y en donde R2 no se sustituye con amina o alquilamina; cada R4 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; m es 0, 1 o 2; cada R5 independientemente es H, alquil, alquenil, alquinil, cicloalquil, o -Ay; p es 0 o 1; Y es -NR10-, -O-, -C(O)NR10-, -NR10C(O)-, -C(O)-, -C(O)O-, -NR10C(O)N(R10)-, -S(O)q-, -S(O)qNR10-, o -NR10S(O)q-; X es -N(R10)2, - RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy, o HetRaHet; cada Ra independientemente es alquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, cicloalquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, alquenileno, cicloalquenileno o alquinileno; cada R10 independientemente es H, alquil, cicloalquil, alquenil, alquinil, cicloalquenil, - Racicloalquil, -RaOH, -RaOR5, -RaNR6R7, o -RaHet; cada uno de R6 y R7 independientemente se seleccionan de H, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Racicloalquil, -RaOH, -RaOR5, -RaNR8R9, -Ay, -Het, -RaAy, -RaHet, o -S(O)qR5; cada uno de R8 y R9 independientemente se seleccionan de H o alquil; cada q independientemente es 0, 1 o 2; cada Ay independientemente representa un grupo aril opcionalmente sustituido; y cada Het independientemente representa un grupo heteroaril o heterociclil opcionalmente sustituido; o ésteres o sales farmacéuticamente aceptables de los mismos. Reivindicacion 58: El proceso para preparar un compuesto de la formula (1), en donde t es 1; cada R es H; cada R1 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; n es 0, 1 o 2; R2 se selecciona de un grupo que consiste de H, alquil, haloalquil, cicloalquil, alquenil, alquinil, -RaAy, -RaOR5, -RaS(O)qR5 o Racicloalquil; cada R4 independientemente es halogeno, haloalquil, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Ay, -NHAy, -Het, -NHHet, -OR10, -OAy, -OHet, -RaOR10, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het, -S(O)2NR6R7, -S(O)qR10, -S(O)qAy, ciano, nitro, o azido; m es 0, 1, o 2; cada R5 independientemente es H, alquil, alquenil, alquinil, cicloalquil, o -Ay; p es 0 o 1; Y es -NR10-, -O-, -C(O)NR10-, -NR10C(O)-, -C(O)-, -C(O)O-, -NR10C(O)N(R10)-, -S(O)q-, -S(O)qNR10-, o -NR10S(O)q-; X es -N(R10)2, - RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, -HetRaAy, o HetRaHet, cada Ra independientemente es alquileno opcionalmente sustituido con uno o más de alquil, oxo o hidroxil, cicloalquileno opcionalmente sustituido con uno o más de alquil, oxo o hidoxil, alquenileno, cicloalquenileno, o alquileno; cada R10 independientemente es H, alquil, cicloalquil, alquenil, alquinil, cicloalquenil, - Racicloalquil, -RaOH, -RaOR5, -RaNR6R7, o -RaHet; cada uno de R6 y R7 independientemente se seleccionan de H, alquil, alquenil, alquinil, cicloalquil, cicloalquenil, -Racicloalquil, -RaOH, -RaOR5, -RaNR8R9, -Ay, -Het, -RaAy, -RaHet, o -S(O)qR5; cada uno de R8 y R9 independientemente se seleccionan de H o alquil; cada q independientemente es 0, 1 o 2; cada Ay independientemente representa un grupo aril opcionalmente sustituido; y cada Het independientemente representa un grupo heteroaril o heterociclil opcionalmente sustituido; comprendiendo la etapa de reaccionar un compuesto de formula (2), en donde R1 y n es segun se define con respecto a la formula (1) con el compuesto de la formula (3), en donde R2, Ra, R4, R5, Y, X, p y m son segun se define con respecto a la formula (1) bajo condiciones de aminacion reductiva para formar un compuesto de la formula (1).
ARP050103666A 2004-09-02 2005-09-01 DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4. AR051565A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60674204P 2004-09-02 2004-09-02
US61076504P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
AR051565A1 true AR051565A1 (es) 2007-01-24

Family

ID=36000724

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103666A AR051565A1 (es) 2004-09-02 2005-09-01 DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.
ARP050103665A AR050302A1 (es) 2004-09-02 2005-09-01 Derivados de imidazo[1,2-a]piridina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP050103665A AR050302A1 (es) 2004-09-02 2005-09-01 Derivados de imidazo[1,2-a]piridina

Country Status (16)

Country Link
US (2) US20070254910A1 (es)
EP (2) EP1799671A4 (es)
JP (2) JP2008511669A (es)
KR (2) KR20070053313A (es)
AR (2) AR051565A1 (es)
AU (2) AU2005279835A1 (es)
BR (1) BRPI0514881A (es)
CA (2) CA2578746A1 (es)
IL (1) IL181419A0 (es)
MA (1) MA28872B1 (es)
MX (2) MX2007002679A (es)
NO (2) NO20071366L (es)
PE (2) PE20060656A1 (es)
RU (2) RU2351592C2 (es)
TW (2) TW200612921A (es)
WO (2) WO2006026703A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511669A (ja) * 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
US7767826B2 (en) * 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
US20100292232A1 (en) * 2007-11-09 2010-11-18 Daniel Elleder Non-nucleoside reverse transcriptase inhibitors
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3390406A1 (en) * 2015-12-15 2018-10-24 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
PT3393468T (pt) 2015-12-22 2023-01-19 X4 Pharmaceuticals Inc Métodos para tratar imunodeficiências
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223239A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US11497744B2 (en) 2017-02-21 2022-11-15 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
US11396501B2 (en) * 2017-09-25 2022-07-26 Cgenetech (Suzhou, China) Co., Ltd. Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same
US11649235B2 (en) 2018-03-19 2023-05-16 Emory University Pan-tropic entry inhibitors
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
WO2002022600A2 (en) * 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
DE60143457D1 (de) * 2000-09-15 2010-12-23 Anormed Inc Chemokin Rezeptor bindende heterozyklische Verbindungen
EP1465889B1 (en) * 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
JP2008511669A (ja) * 2004-09-02 2008-04-17 スミスクライン ビーチャム コーポレーション 化合物
US20080171740A1 (en) * 2004-09-24 2008-07-17 Smithkline Beecham Corporation Chemical Compounds
WO2007027999A2 (en) * 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
WO2006026703A8 (en) 2006-05-26
PE20060656A1 (es) 2006-08-24
TW200612921A (en) 2006-05-01
CA2579059A1 (en) 2006-03-16
RU2351592C2 (ru) 2009-04-10
MX2007002615A (es) 2007-04-27
MA28872B1 (fr) 2007-09-03
WO2006028896A3 (en) 2006-04-27
NO20071418L (no) 2007-05-31
CA2578746A1 (en) 2006-03-09
US20070232615A1 (en) 2007-10-04
JP2008511669A (ja) 2008-04-17
WO2006028896A2 (en) 2006-03-16
WO2006026703A3 (en) 2006-10-05
KR20070049682A (ko) 2007-05-11
AU2005279835A1 (en) 2006-03-09
RU2352567C2 (ru) 2009-04-20
TW200621754A (en) 2006-07-01
US20070254910A1 (en) 2007-11-01
AU2005282753A1 (en) 2006-03-16
IL181419A0 (en) 2007-07-04
EP1784185A2 (en) 2007-05-16
AR050302A1 (es) 2006-10-11
NO20071366L (no) 2007-05-31
RU2007106779A (ru) 2008-10-10
EP1799671A2 (en) 2007-06-27
PE20060712A1 (es) 2006-08-24
EP1799671A4 (en) 2009-06-10
EP1784185A4 (en) 2009-06-03
JP2008511668A (ja) 2008-04-17
WO2006026703A2 (en) 2006-03-09
KR20070053313A (ko) 2007-05-23
BRPI0514881A (pt) 2008-06-24
MX2007002679A (es) 2007-05-16
RU2007106780A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
AR051565A1 (es) DERIVADOS DE IMIDAZO[1, 2 - A]PIRIDINA; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES E INFECCIONES POR VIH MEDIADAS POR CXCR4.
AR050522A1 (es) Derivados de bencimidazol como moduladores de la actividad de los receptores de quimioquina; composiciones farmaceuticas que los contienen; metodos para su preparacion y su uso en la fabricacion de medicamentos para el tratamiento contra infecciones por hiv
AR059197A1 (es) Derivados de indazolo piridina para el tratamiento de hiv
AR035664A1 (es) Imidazo[4,5-c]quinolin-4-aminas y tetrahidroimidazo[4,5-c]quinolin-4-aminas, composiciones farmaceuticas que las comprenden, uso de dichos compuestos en la preparacion de medicamentos, e intermediarios utiles en la sintesis de dichos compuestos
AR082995A1 (es) Profarmacos que comprenden un conjugado de conector de exendina
CA2972017C (en) Isoquinoline compounds for the treatment of hiv
PE20120106A1 (es) Moduladores de receptores tipo toll
UY29827A1 (es) 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
AR030152A1 (es) Uso de benzimidazoles e imidazopiridinas para la preparacion de medicamentos para el tratamiento de infecciones virales, benzimidazoles e imidazopiridinas, productos y composiciones farmaceuticas que los comprenden y procesos para prepararlos
AR034261A1 (es) Compuestos derivados de pirazol[1,5-a]piridina; composiciones farmaceuticas, su uso en la fabricacion de medicamentos, y metodos de tratamiento de enfermedades mediadas por quinasas
BRPI0507065B8 (pt) derivados de quinolina, composição que os compreende, seu processo de preparação e seu uso como inibidores micobacterianos
BR112014011850A8 (pt) Derivados de aminopirimidina, seus usos, e composição farmacêutica
NI201500160A (es) Derivados 11-hidroxilo de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores del receptor de farnesoid x
UY30183A1 (es) Derivados de quinolina
ECSP12011838A (es) Derivados de la cromenona con actividad anti-tumoral
RU2008136898A (ru) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
AR029811A1 (es) Un procedimiento para la preparacion de una sal de citalopram, base cristalina de citalopram obtenida por dicho procedimiento y una composicion farmaceutica
UY28578A1 (es) Derivados de amida
MX2009004780A (es) Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico.
BRPI0907789A2 (pt) derivaldos 16-alfa e 17-alfa de glicocorticosteroides e seus usos
AR078121A1 (es) Compuestos de sales de amonio cuaternario y composiciones farmaceuticas
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal